Novo Nordisk announces expansion of Hillerød API manufacturing facility
Novo Nordisk will invest 15.9 billion Danish kroner into the expansion of their existing API manufacturing facility.
Novo Nordisk have announced on June 12, 2023 that they are to invest DKK 15.9 billion kr. for the expansion of their API manufacturing facility in Denmark for products that treat serious chronic diseases, such as diabetes.
The current production facility, located in Hillerød, Denmark, will benefit from the investment with increased production capacity and enable the Danish pharmaceutical company to meet market demands in the future regarding drug products for chronic diseases. The facility will particularly develop Novo Nordisk’s ability to develop a clinical late-phase product portfolio in the future.
An additional 65,000 m2 will be added to design a multi-product facility and house state-of-the-art technology to ensure flexibility in accommodating new processes. The new facility will be geared towards delivering high-quality drug products compliant with environmental sustainability regulations through the use of compact and optimal process flow that reduce the consumption of water and energy. Construction has already begun, with the facility to start producing APIs by 2029, creating 340 new jobs within the region.
Henrik Wulff, Executive VP of Product Supply, Quality & IT at Novo Nordisk, highlighted the importance of the investment and the healthcare opportunities that can be provided with the right infrastructure: “This important investment will ensure the continuous development of our late-phase pipeline into deliveries of important medicines for treatments to patients worldwide,” he commented. “The investment announced today confirms Hillerød and Denmark as cornerstones in our global footprint, and I would like to take this opportunity to thank the Danish Government and Parliament for their continued focus on ensuring good and stable infrastructure and supplies – allowing us to continue to expand our production capacity to the benefit of patients living with serious chronic diseases.”
Source: Novo Nordisk invests DKK 15.9 bn in expansion of manufacturing facilities in Hillerød, Denmark [Accessed June 12, 2023] https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=166116
Related News
-
News How to disrupt an industry as big as pharma for the better?
In this interview, hear from Matthew Wise, Head of Data at CCD Partners, on the companies they've been looking into that are offering new and interesting perspectives that have the potential to shake up the pharmaceutical industry, and how they'... -
News CPHI Pharma Awards 2024: Meet the winners from the CPHI Celebration
This year we had a lot to celebrate, the 35th Anniversary of CPHI, and our esteemed award winners, of which we included two additional categories this year, the Future Leader award, and Woman of the Year award. -
News CPHI Milan 2024 - From the Floor
Milan and CPHI welcome you to 2024 CPHI Milan! As we celebrate the 35th edition of our flagship CPHI show, editors Vivian Xie and Lucy Chard bring you the latest from the show floor, conference sessions, and innovative solutions from all exhibitors, at... -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News A Day in the Life of a Global CDMO Chapter Lead – Manufacturing
The 'Day in the Life of' series has covered many aspects of the pharmaceutical pipeline, including R&D and procurement, now we're taking a look at manufacturing from a global CDMO perspective. -
News Eisai Alzheimer’s drug authorised in UK but still faces obstacles
In partnership with BioArctic AB, pharmaceutical company Eisai has been granted Marketing Authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) for its Alzheimer’s disease drug product Leqembi. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance